EGFR and non-small cell lung carcinoma: The three-year period prescribing prevalence of EGFR-positive NSCLC was estimated at 10.09 per 100,000 males (95% CI: 9.25–10.92) and 13.99 per 100,000 females (95% CI: 12.89–15.07), yielding an overall prevalence of 11.84 per 100,000 population (95% CI: 11.16–12.51).